Kinetic measures of a cerebrospinal fluid (CSF) biomarker test predicted cognitive decline in Parkinson's disease and ...

Dr. Bernick said the new blood test, which was just approved by the FDA, is for adults over the age of 55 who are showing signs of Alzheimer’s disease. Alzheimer’s is the most common cause for ...

Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison ...

With the registration, the analyzer can be used for clinical testing in South Korea, expanding Quanterix's reach in that country's in vitro diagnostic and clinical laboratory markets.

Northwestern Medicine scientists have uncovered key details about a group of rare but serious blood disorders, which may help ...

Patna: Patna divisional commissioner Chandrashekhar Singh on Monday ordered immediate activation of the non-functional central sterile supply departme.

Virohan partners with Orange Health Labs to provide diagnostic internships and job opportunities for Medical Laboratory ...

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 ...

A rare gene mutation that delays Alzheimer's disease does so by damping inflammatory signaling in brain-resident immune cells ...

A former GP accused of conducting unnecessary genital examinations on nine male patients was “haunted” by earlier ...

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting ...

The global biomarkers market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to ...